(Q39246575)

10 September 2017

title

In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation (English)

1 reference

10 September 2017

1 reference

Wei-Hua Hao

1

1 reference

10 September 2017

Jong-Jing Wang

2

1 reference

10 September 2017

Shu-Ping Hsueh

3

1 reference

10 September 2017

Pei-Jing Hsu

4

1 reference

10 September 2017

Li-Chien Chang

5

1 reference

10 September 2017

Chang-Shan Hsu

6

1 reference

10 September 2017

Kuang-Yang Hsu

7

1 reference

10 September 2017

publication date

10 November 2012

1 reference

Cancer Chemotherapy and Pharmacology

10 September 2017

published in

1 reference

10 September 2017

volume

71

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

379-388

1 reference

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Treatment of classical Kaposi's sarcoma with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Applications of microemulsion based drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Model-based drug development: the road to quantitative pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2017-5

10.1007/S00280-012-2017-5

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference